DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the DRA Consultants Ltd (DRA) share price today?

DRA Consultants Ltd (DRA) is trading at ₹18 on the BSE, down 12.20% on the day. Source: DocStoX.

What is the PE ratio of DRA Consultants Ltd?

DRA Consultants Ltd has a price-to-earnings (PE) ratio of 16.7 in the Healthcare sector.

What is the market capitalisation of DRA Consultants Ltd?

DRA Consultants Ltd has a market capitalisation of approximately ₹20 crore.

Is DRA Consultants Ltd a profitable company?

DRA Consultants Ltd generates a return on equity of 8.1% with a net profit margin of 11.3%. That is a modest return on shareholder capital.

What is the 52-week high and low of DRA?

DRA Consultants Ltd (DRA) has traded between ₹11.55 and ₹21 over the past 52 weeks, against a current price of ₹18.

DRA Consultants Ltd

₹18.00▼ -2.50 (-12.20%)

DRA·BSE·Healthcare

Market Cap

19.75 Cr

PE Ratio

16.67

Volume

5,000

Day High - Low

18.00 - 18.00

52W High-Low

21.00 - 11.55

₹18.00▼ -2.50 (-12.20%)

Market Cap19.75 Cr

PE Ratio16.67

Volume5,000

Day High - Low18.00 - 18.00

52W High-Low21.00 - 11.55

DRA Consultants Ltd (DRA): company summary

The company's annual revenue rose 19.2% to ₹26 crore, but the latest quarter revenue fell 36.2% to ₹1 crore compared to the same quarter a year earlier.

DRA Consultants Ltd (DRA) is a micro-cap Healthcare company valued at ₹20 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: DRA Consultants Ltd last traded at ₹18, sharply down 12.20% on the day.
Recent developments: On 2026-06-30, the company reported a net profit of ₹0 crore for the latest quarter, down 20.0% from the year-ago quarter. On 2026-03-31, the company reported a net profit of ₹0 crore, which was flat compared to the prior quarter. On 2025-12-31, the company reported a net profit of ₹0 crore, which was flat compared to the prior quarter.
Financial performance: The company's annual revenue rose 19.2% to ₹26 crore, but the latest quarter revenue fell 36.2% to ₹1 crore compared to the same quarter a year earlier. Annual net profit increased 7.4% to ₹3 crore, while the latest quarter net profit remained at ₹0 crore, down 20.0% from the year-ago quarter. The net profit margin narrowed 1.2 percentage points to 11.3%, and return on equity remained at 8.1%.
Valuation multiples: The stock trades at 16.7 times earnings, a discount to the Healthcare median of 32.0, 1.18 times book value.
Things to watch: The company's latest quarter net profit remained at ₹0 crore, down 20.0% from the year-ago quarter. Promoter holding fell 22.99 percentage points to 50.03% as of 2026-06-30. The stock is 2.4% below its 52-week high.
Where it stands: The company's annual revenue grew 19.2% to ₹26 crore, but the latest quarter revenue fell 36.2% to ₹1 crore. The stock is 2.4% below its 52-week high, and promoter holding dropped 22.99 percentage points to 50.03%.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

6.7/10

Fair

Fair Value

ROE

8.10%

Average

P/E

16.67x

Fair

Debt / Equity

0.01

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Fair

Price performance

52W₹11.55

₹21.00

DocStoX take

Supported by growth (8.7) and risk (7.8), but weakest on quality (4.4).

DocStoX score

Low confidence

6.7

/10

Fair

Quality

Modest

ROE 8.1%

Valuation

Fair

P/E 16.7×

Growth

Strong

Revenue +31.3% 5Y CAGR

Risk

Low risk

D/E 0.01

Momentum

Strong

68% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹18

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹20 Cr

52W High / Low

₹21 / ₹12

Dividend Yield

0.00%

Promoter Holding

50.03%

EPS (TTM)

₹1.08

Book Value

₹0.00

Key highlights

Profit compounding 47% a year
Revenue compounding 31% a year
Low leverage — D/E 0.01
Small ₹20 cr company — thinner liquidity

4 Positives1 Watchout

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore DRA Consultants Ltd’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

DRA Consultants Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Laurus Labs Limited Zydus Lifesciences Limited Apollo Hospitals Enterprise Limited Cipla Limited Dr. Reddy's Laboratories Limited Mankind Pharma Limited Aurobindo Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare DRA Consultants Ltd with peers

DRA Consultants Ltd vs Sun Pharmaceutical Industries Limited DRA Consultants Ltd vs Divi's Laboratories Limited DRA Consultants Ltd vs Torrent Pharmaceuticals Limited DRA Consultants Ltd vs Laurus Labs Limited DRA Consultants Ltd vs Zydus Lifesciences Limited DRA Consultants Ltd vs Apollo Hospitals Enterprise Limited

Related tools & concepts

Value DRA Consultants Ltd with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

DRA newsLatest coverage & filings Open screenerFilter the whole market